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Inﬂammation results from the complex interaction between hematopoietic and stromal
cells and growing evidence supports a key role for the stroma in driving the switch from
acute resolving to persistence in chronic inﬂammatory diseases. Stromal cells have also
been shown to play a critical role in cancer biology, being involved in cancer growth,
dissemination, and inhibition of the autologous immune response, ultimately favoring
persistence and metastatic spread. Similarly, blood and lymphatic endothelial cells
contribute to tissue homeostasis during physiological inﬂammation but also lead to
discorded leukocyte and tumor cell accumulation in pathological inﬂammation and cancer.
This review aims to summarize the role that pathogenic stroma plays in the pathogenesis
of diseases such as cancer and chronic inﬂammation.
Keywords: endothelium, lymphatics, rheumatoid arthritis, ectopic lymphoneogenesis, fibroblasts
INTRODUCTION
Inﬂammation involves the complex interaction between inﬁltrat-
ing cells, belonging to the immune system and tissue-resident
stromal cells. The stroma, formerly considered the theatrical stage
of the inﬂammatory process, has acquired, in recent years the
role of director of the immune response, regulating the process
of leukocyte recruitment, organization of leukocytes within the
tissue and exit via the escape route of the lymphatic endothelium.
In physiological conditions, stromal cells provide an important
structural component for tissues. Stroma consists of extracellular
matrix (ECM),mesenchymal cells and a scaffold of nerves, epithe-
lium, blood, and lymphatic vessels. Tissue-resident macrophages,
although considered by some as part of the tissue stroma,
are largely bone marrow-derived and bear the hallmark of the
hematopoietic tissue.
Under pathogen threat or in the target tissue of chronic inﬂam-
mation and cancer, stromal cells acquire novel features, critical for
the development of the pathological process and functional for
its persistence. This review will provide the reader with a better
understanding of the role of pathogenic stroma in inﬂammation.
As both epithelium and nerves appear to be more implicated in
disease initiation, rather than persistence, this review will focus on
the role of ﬁbroblasts, lymphatic and blood vessels.
FIBROBLASTS
The most abundant cell type within tissue stroma is the ﬁbrob-
last (Filer et al., 2006). Fibroblasts are traditionally deﬁned by
their spindle shaped morphology and their ability to adhere to
plastic culture vessels in vitro (Tarin and Croft, 1969). They are
believed to arise from three distinct cellular origins: primary
mesenchyme, local epithelial-mesenchymal transition (EMT), or
bonemarrow-derived precursors (circulating ﬁbrocytes; Abe et al.,
2001; Kalluri and Neilson, 2003). It is widely accepted that the
majority of ﬁbroblasts originate from primary mesenchymal cells
and that, upon appropriate stimulation, ﬁbroblasts proliferate
to generate new progeny (Iwano et al., 2002; Parsonage et al.,
2005). In physiological conditions ﬁbroblasts provide mechanical
strength to tissues by producing ECM components (type I, III, and
V collagen and ﬁbronectin), factors that regulate ECM turnover,
such as metalloproteinases (MMPs) and proteins involved in the
formation of basement membrane (type IV collagen and laminin;
Marinkovich et al., 1993; Sabatelli et al., 2001; Tomita et al., 2002).
The intimate relationship between ﬁbroblasts and mesenchymal
stromal cells (MSC) and the clinical challenge to use MSC for tis-
sue repair has driven renewed interest in ﬁbroblasts as therapeutic
target. Our group has largely contributed to this characterization
utilizing antibodies raised against different components of this
heterogeneous population. This screening exercise has provided
us with some key markers that, together with others present in the
literature (Table 1), can now be used to better understand distri-
bution, function, and plasticity of the complex ﬁbroblast family
(Buckley et al., 2005; Halder et al., 2005).
Fibroblast behavior has mainly been explored in three patho-
logical conditions: chronic inﬂammation, tissue ﬁbrosis, and
cancer. Interestingly, while these three conditions dramatically
differ in etiology and genetic predispositions, they converge in
that there are profound modiﬁcations both in terms of phenotype
and function occurring to the stromal component. Whether these
newly acquired properties are intrinsic to changes occurring in
the ﬁbroblasts or derive from the conditioning of the pathogenic
inﬁltrating cells is still under investigation and seems to differ in
the diverse conditions (Buckley et al., 2001).
www.frontiersin.org January 2013 | Volume 3 | Article 416 | 1
“ﬁmmu-03-00416” — 2013/1/10 — 19:54 — page 2 — #2
Barone et al. Stromal cells in inﬂammation
Table 1 | Fibroblast markers.
Marker Function Fibroblast subtype Other expressing cells
Vimentin Intermediate ﬁlament associated protein Miscellaneous Endothelial cells, myoepothelial cells, neurons
α-SMA Intermediate ﬁlament associated protein Myoﬁbroblasts Vascular smooth muscle cells, pericytes,
myoepithelial cells
Desmin Intermediate ﬁlament associated protein Skin ﬁbroblasts Muscle cells, vascular smooth muscle cells
FSP1 Intermediate ﬁlament associated protein Miscellaneous Invasive carcinoma cells
Discoidin-domain receptor 2 Collagen receptor Cardiac ﬁbroblasts Endothelial cells
FAP Serine protease Activated ﬁbroblasts Activated melanocytes
α1β1 integrin Collagen receptor Miscellaneous Monocytes, endothelial cells
Prolyl 4-hydroxylase Collagen biosynthesis Miscellaneous Endothelial cells, cancer cells, epithelial cells
Pro-collagen 1α2 Collagen-1 biosysnthesis Miscellaneous Osteoblasts, chondroblasts
CD248 Unknown Miscellaneous Pericytes
VCAM-1 Cell adhesion Miscellaneous Activated endothelial cells
Adapted from Kalluri and Zeisberg (2006).
Fibroblasts play a crucial role in determining the site at which
inﬂammation occurs, and inﬂuence the persistence of the inﬂam-
matory process (Takemura et al., 2001). Different events have been
shown to take place in order to elicit themodiﬁcations required for
ﬁbroblast activation. Signals derived from the surrounding inﬁl-
trating cells, such as proinﬂammatory cytokines have been shown
toplay a key role in the activationof rheumatoid arthritis (RA) syn-
ovial ﬁbroblasts (Ohata et al., 2005). Similarly, leukocyte-derived
signals such as IL-4 (Th2), interferon gamma (Th1), and TNF
have been shown to modify the ﬁbroblast transcriptional proﬁle
(Parsonage et al., 2003). Nonetheless, a growing body of evidence
suggests that intrinsic events such as the occurrence of epigenetic
modiﬁcations in the ﬁbroblast genome might contribute to the
persistence of the activated phenotype (Ospelt et al., 2011).
Once activated, synovial ﬁbroblasts have been shown to pro-
duce TNFα, IL-1, and IL-6, cyclooxygenase-2, the polysaccharide
hyaluronan, as well as inﬂammatory chemokines (e.g., IL-8, CCL5,
CXCL1; Szekanecz et al., 2003; Iwamoto et al., 2008), thus sustain-
ing leukocyte recruitment in to the inﬂamed synovium. Fibroblasts
play not only a key role in immune cell recruitment but also in
leukocyte aggregation within tissue. Pathogenic ﬁbroblasts have
been implicated in the formation of tertiary lymphoid organs
(TLOs), lymph node like structures, resulting from the organized
aggregation of leukocytes inside tissue target of inﬂammatory pro-
cesses (Buckley et al., 2000). Recent work of Peduto et al. (2009)
has described early modiﬁcations occurring to normal stromal
ﬁbroblasts following inﬂammatory stimuli, like the re-expression
of the ﬁbroblast embryonic marker gp38, that result in the acquisi-
tion of a lymphoid like phenotype able to sustain TLO formation.
Gp38 is a glycoprotein characterized by Farr et al. (1992), later
named podoplanin due to its low level constitutive expression
in kidney podocytes (Breiteneder-Geleff et al., 1997). Gp38 (or
podoplanin in humans) is expressed by lymphoid stromal cells
within the T cell areas of peripheral lymphoid tissue (Farr et al.,
1992), in the medulla and paracortex of lymph nodes, within the
peri-arteriolar region of the splenic white pulp (PALS), on the
lymphatic endothelial cells (Schacht et al., 2003) and on thymic
epithelial cells (Farr et al., 1992). The role of gp38 + ﬁbroblasts
in the production of lymphoid cytokines and chemokines in sec-
ondary lymphoid organs has been reviewed elsewhere and will not
be discussed further in this review (Astarita et al., 2012).
In physiological conditions, within non-lymphoid tissue,
ﬁbroblasts do not express gp38. Interestingly, the phenomenon of
up-regulation of this marker coincides with the capacity of tissue-
resident ﬁbroblasts to “convert to a lymphoid-like” functional
phenotype. Lymphoid-like ﬁbroblasts express CD157 (BP-3) and
produce IL-7 and lymphoid chemokines CXCL13 and CCL19
which are able to drive accumulation and segregation of the leuko-
cytes in distinct compartmentswithin the inﬂamed joints (Buckley
et al., 2000, 2001; Bradﬁeld et al., 2003; Peduto et al., 2009). The
histological ﬁnding of TLOs in RA synovium has been associated
with severe disease progression and erosions (van de Sande et al.,
2011). TLOs are not speciﬁc to RA and other chronic diseases, such
as Sjogren’s syndrome,Hashimoto thyroiditis, and Crohn’s disease
share a similar pattern of ﬁbroblast activation and production of
lymphoid cytokines/chemokines (Aloisi and Pujol-Borrell, 2006).
Rheumatoid arthritis synovial ﬁbroblasts produce survival fac-
tors (e.g., type I interferon, IL-15, BAFF) that inhibit leukocyte
apoptosis (Pilling et al., 1999; Burger et al., 2001). Gp38 expression
is associatedwith the acquisitionof amotile, contractile phenotype
and it has been detected in cells derived from various types of can-
cers (i.e., vascular tumors, tumors of the central nervous system,
malignant mesothelioma, squamous cell carcinomas, and germ
cell tumors). Gp38 expression seems to identify more aggressive
forms of tumors, with higher invasive and metastatic potential
(Schacht et al., 2005; Raica et al., 2008). Gp38 is expressed both
by tumor cells and by the cancer-associated ﬁbroblasts (CAF),
a population of ﬁbroblasts that surrounds and mingle with the
malignancy favoring its organization and metastasis in to the
surrounding tissue. The expression of gp38 in the context of
tumor-associated lymphangiogenesis will be later discussed. CAF
as well as ﬁbroblasts from the inﬂamed synovium are also charac-
terized by FAP (ﬁbroblast activation protein) expression (Ospelt
et al., 2010).
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Fibroblast activation protein, also known as “seprase,” is a cell-
surface 170 kDa type II transmembrane serine protease (Rettig
et al., 1986; Aoyama and Chen, 1990), belonging to the family of
post-prolyl aminopeptidases (Niedermeyer et al., 1998). Dipep-
tidyl peptidase IV (DPPIV or CD26) is the most studied closest
member to FAP, with 61% nucleotide sequence and 48% amino
acid sequence identity (Scanlan et al., 1994). FAP was identi-
ﬁed as an inducible antigen by F19 monoclonal antibody and
expressed on developing (Rettig et al., 1988; Garin-Chesa et al.,
1990; Niedermeyer et al., 2001) and reactive mesenchyme of var-
ious tumors, transformed cell lines, and granulation tissue of
wound healing (Rettig et al., 1986, 1988; Aoyama and Chen, 1990;
Garin-Chesa et al., 1990; Kelly et al., 1994; Monsky et al., 1994).
When over-expressed in epithelial and ﬁbroblastic cell lines, FAP
has been proven to affect cell adhesion, migration, proliferation,
and apoptosis (Wang et al., 2005).
Recently a novel immunosuppressive role for FAP-positive
ﬁbroblasts has been shown in the tumor environment. By using a
FAP-DTR mice, in which deletion of FAP+ ﬁbroblasts is induced
upon diphteria toxin administration, Kraman et al. (2010) have
shown that depletion of FAP-expressing cells in Lewis lung carci-
noma and pancreatic ductal adenocarcinoma causes rapid hypoxic
necrosis of both tumor and stromal cells by a process involving
IFNγ and TNFα. These studies support the hypothesis that FAP
activity and FAP-expressing ﬁbroblasts facilitate tumor growth
both directly aswell as acting on the immune cells recruited against
the malignancy. This suggests that cancerous cells, early in the dis-
ease establishment are able to modify the local environment and
induce the formation of a stroma able to protect the same malig-
nancy against the self-immune-surveillance, thus establishing a
novel immunological role for stromal cells in cancer persistence
and spreading.
VASCULAR STRUCTURES
LYMPHATIC VESSELS
Striking changes in the lymphatic vasculature are associated
with inﬂammation, which include acute and chronic infections,
autoimmune diseases such as RA, Crohn’s disease, wound heal-
ing, cancer, and transplant rejection (Tammela and Alitalo, 2010;
Alitalo, 2011). Neo-lymphangiogenesis is a critical mechanism
regulating changes in interstitial ﬂuid. Deregulated activation of
its cascade results in defective leukocyte drainage and persistence
of the inﬂammatory process. Recent studies show that induction
of the NF-κB pathway activates Prox1 and this in turn activates
the expression of the VEGFR-3 promoter, leading to increased
receptor expression on lymphatic endothelial cells. This phe-
nomenon enhances the responsiveness of pre-existing lymphatic
endothelium to VEGFR-3 ligands, VEGF-C and VEGF-D, which
stimulates lymphangiogenesis (Alitalo et al., 2005; Zhang et al.,
2007; Watari et al., 2008; Kang et al., 2009; Flister et al., 2010).
Other proinﬂammatory cytokines, e.g., IL-1 and TNFα are known
to induce VEGF-C/D expression in inﬁltrating and tissue-resident
cells such as macrophages, dendritic cells (DCs), mast cells, and
ﬁbroblasts (Ristimaki et al., 1998; Hamrah et al., 2003; Cursiefen
et al., 2004; Alitalo et al., 2005; Baluk et al., 2005; Kataru et al.,
2009; Kunder et al., 2009, 2011; Yao et al., 2010; Zumsteg and
Christofori, 2012). Similarly, LTα secreted by lymphocytes at the
site of inﬂammation has been documented to support inﬂam-
matory lymphangiogenesis (Mounzer et al., 2010). Data from
models of inﬂamed cornea in mice and renal transplant induced
inﬂammation inhumanshave shown that inﬂammation-mediated
lymphangiogenesis does not occur solely by proliferation or con-
tinuous sprouting of existing lymphatic vessels but also includes
incorporation of BM-derived lymphangiogenic progenitors (such
as CD11b+macrophages) into the existing or growing lymphatic
vessels. These CD11b + progenitors have the capability to trans-
differentiate into LYVE + vessels under pathological conditions,
contributing to the increased lymphatic vessel density observed
at inﬂammatory sites (Maruyama et al., 2005; Kerjaschki et al.,
2006; Maby-El Hajjami and Petrova, 2008; Lee et al., 2010). Lym-
phangiogenesis is thought to facilitate resolution of inﬂammation,
providing drainage of tissue edema, clearance of inﬂammatory
cells and also favoring adaptive immune cell function by pro-
moting macrophage and DCs mobilization to the draining lymph
nodes. Inhibiting lymphangiogenesis by blocking VEGFR activ-
ity exacerbates pulmonary edema and favors the establishment
of chronic mycoplasma infection (Baluk et al., 2005; Polzer et al.,
2008; Kataru et al., 2009; Huggenberger et al., 2011; Kim et al.,
2012). Taken together, these data suggest that the signals that
activate the induction of the inﬂammatory process also program
its resolution. It is believed that such a coordinated series of
events is altered in chronic inﬂammation, where the number
of the inﬁltrating leukocytes overcome the drainage capacity of
the newly developing lymphatics. It is debatable whether newly
formed lymphatic vessels are able to establish functional connec-
tions and deliver antigen, ﬂuid, and cells to the draining lymph
nodes. The inability of lymphatic vessels to deliver antigens to
the draining lymph node could favor the persistence of TLOs,
where an excess of antigen is presented in structures whose stroma
component is potentially unable to exert the tollerogenic activ-
ity attributed to lymph node stroma (Kline and Thomas, 1976;
Eliska et al., 1986; Joos et al., 1993; Ruggiero et al., 1994; Angeli
et al., 2006; Angeli and Randolph, 2006; Thaunat et al., 2006; Li
et al., 2011). In this context the ectopic expression of CCL21 on
newly formed (but yet non-functional lymphatic vessels) might
compete with the chemokine gradient established by pre-existent
functional lymphatic vessels, thus contributing to the entrapment
of leukocytes and DCs within the TLOs (Kerjaschki et al., 2004;
Burman et al., 2005).
Lymphatic vessels have also been shown to play a role in
immune regulation. For example the decoy chemokine receptor
D6, which acts as a scavenger of inﬂammatory CC chemokines, is
known to be expressed on lymphatic endothelium (Nibbs et al.,
2001; Jamieson et al., 2005; Martinez de la Torre et al., 2005).
In addition, inﬂamed lymphatic endothelium mediates suppres-
sion of DC maturation via CD11b interaction with ICAM-1
receptor (expressed on lymphatic endothelial cells; Podgrabinska
et al., 2009).
However, lymphangiogenesis is a double-edged sword, as
tumor cells can use this process as amechanism to drivemetastasis.
Tumor cells enter lymphatic vasculature by invading pre-existing
lymphatic vessels or by eliciting neo-lymphangiogenesis on the
periphery of the tumor, stimulating the secretion of growth factor
(VEGF) on tumor-associated ﬁbroblasts andmacrophages (Jeltsch
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et al., 1997; Karpanen et al., 2001; Mandriota et al., 2001; Skobe
et al., 2001; Stacker et al., 2001; Schoppmann et al., 2002). Inter-
estingly, high density of lymphatic vessels correlates with high
incidence of lymph node metastasis and poor prognosis in some
cancers (Beasley et al., 2002; Alitalo et al., 2005; Cao, 2005; Kyzas
et al., 2005). As mentioned above, gp38 is highly expressed on
the lymphatic endothelium and its expression correlates with
poor prognosis and increased risk of lymph node metastasis
(Schacht et al., 2005; Kitano et al., 2010). Lymphangiogenesis
has also been found to play a pathogenic role in transplanta-
tion biology where it sustains delivery of donor antigens to the
recipient lymph node, ultimately favoring the generation of an
immune response against the transplanted tissue (Tammela and
Alitalo, 2010; Alitalo, 2011; Seeger et al., 2012). These data sug-
gest a key role for lymphatic vessel function and homeostasis
in the regulation of the balance between immunity and toler-
ance as well the persistence of inﬂammation compared to its
resolution.
BLOOD VESSELS
Similar to the ﬁbroblasts and lymphatic vessels, blood vessels
undergo remodeling during inﬂammation. Blood endothelium
changes its structure andphenotype andparticipates in the inﬂam-
matory response mainly regulating leukocyte recruitment into
the tissue. This phenomenon is characterized by loss of vascu-
lar integrity, which results in exposure of the sub-endothelium
matrix and efﬂux of plasma-protein rich from the intravascular
space (Pober and Sessa, 2007). The newly formed extravascular
matrix supports leukocyte extravasations and it is associated with
the expression of leukocyte adhesion molecules such as E-selectin,
VCAM-1, and ICAM-1 (Adams and Shaw, 1994; Clark et al., 2006;
Ley and Reutershan, 2006). Inﬂammatory stimuli such TNFα, IL-
1, certain bacteria and viruses, physical and oxidative stress (Pober
and Sessa, 2007), and anti-endothelial cell antibodies (found in
systemic inﬂammatory disease such as vasculitides; Meroni et al.,
1995) all elicit NF-κB translocation and binding to promoter
regions of genes commonly up-regulated during blood endothe-
lial cell activation (Bierhaus et al., 1997; Hunt and Jurd, 1998;
Pober and Sessa, 2007). Failure to restore homeostasis of the blood
endothelium contributes to chronic inﬂammatory disease and
edema. Activated blood endothelial cells synthesize cytokine such
as IL-6, which regulates the acute phase response, and chemoat-
tractants, such as IL-8 and MCP-1 that help establishing the
chemotactic gradient necessary for the inﬂux of various inﬂamma-
tory cells into the site of inﬂammation (Pober and Cotran, 1990;
Mantovani et al., 1997; Middleton et al., 1997). Blood endothelial
cells are also able to act as an antigen-presenting cell, express-
ing class II HLA molecules, in a phenomenon that has been
shown to contribute to transplant rejection (Pober et al., 1996).
Expression of co-stimulatory molecules such as OX40, ICOS, and
CD2, known to be important in the formation and activation
of T cell memory, has been documented in activated human
endothelial vessels (Shiao et al., 2005), suggesting a role for the
endothelium not only in leukocyte recruitment but also in their
education.
Additional endothelial changes are observed in various chronic
inﬂammatory diseases, such as Sjogren’s syndrome, thyroiditis,
and RA. As mentioned above, chronically inﬂamed organs often
acquire TLOs that are accompanied by conversion of ﬂat venu-
lar endothelial cells into tall and plump endothelial cells that
very closely resemble high endothelial venules (HEVs) found in
the T cell rich area of the lymph node. These ectopic HEVs
are characterized by expression of the lymph node trafﬁcking
code, Peripheral node addressin (PNAd) that binds L-selectin
expressed on naïve/central memory T lymphocytes and mature
DCs. This homing machinery, supported by the ectopic expres-
sion of CCL21, allows HEVs in peripheral tissue to misguide
inﬂux of CCR7 + memory T cells into the inﬂamed tissue
leading to ampliﬁcation and maintenance of chronic inﬂam-
mation (Girard and Springer, 1995; Barone et al., 2005; Manzo
et al., 2005; Aloisi and Pujol-Borrell, 2006). Our group has
recently demonstrated that endothelium cultured with ﬁbroblasts
derived from inﬂamed synovium behaves differently in terms of
leukocyte recruitment compared to endothelium cultured with
healthy dermal ﬁbroblasts (McGettrick et al., 2009). While rein-
forcing the concept that ﬁbroblasts convey site speciﬁcity to the
immune response, these data highlight the active role of the
stroma in the shaping of the immune response from its earliest
phases.
Growth of new blood vessels from existing ones is a very
important component of many diseases including cancer and
chronic inﬂammation (Pandya et al., 2006; Costa et al., 2007).
Angiogenesis in these conditions ensures continuous oxygen and
nutrient supply to pathogenic cells, thus sustaining their growth
and survival. Several cells types including malignant cells, syn-
ovial ﬁbroblasts, keratinocytes, and monocytes/macrophages are
capable of producing classic angiogenic factors (such as VEGFα,
angiopoetin, and PDGF)when the environment becomes hypoxic.
Moreover, inﬂammatory cytokines such as IL-1, TNFα (low
dose), and IL-8 have been reported to be pro-angiogenetic, thus
supporting this process while exerting other proinﬂammatory
activity. Blood vessels formed during pathological angiogenesis
are structurally and functionally abnormal. Tumor vasculature
is highly disorganized, vessels are tortuous and dilated, with
uneven diameter, excessive branching and shunts that lead to
chaotic and variable blood ﬂow, often resulting in the establish-
ment of hypoxic and acidic areas in the malignant tissue. The
chaotic architecture and disturbed blood ﬂow contributes to lower
therapeutic effectiveness for several drugs (Jain, 1988; Giaccia,
1996; Helmlinger et al., 1997; Baish and Jain, 2000; Eberhard
et al., 2000). Malignancy-associated neo-vascularization shows a
non-uniform pattern of adhesion molecules that coupled with
distorted blood supply (Huang et al., 1997; Eliceiri and Cheresh,
1999) might explain why leukocyte-endothelial interaction is low
in cancer. Similarly, the new vessels formed at the site of inﬂam-
mation also exhibit structural and functional abnormalities. In
RA, the vascular network is reported to be dysfunctional as it
is unable to restore tissue oxygen homeostasis and the rheuma-
toid joints are believed to remains markedly hypoxic during
disease (Taylor and Sivakumar, 2005). In both tumor and RA
impaired angiogenesis ultimately favors the selection of cells that
are metabolically resistant to lack of oxygen, thus reducing the
effectiveness of therapy aimed to disturb the neo-angiogenetic
process.
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CONCLUSION
Current treatments targeting leukocytes have led to a dramatic
change in the management of inﬂammatory disease. However,
this approach does not result in a deﬁnitive cure and even in
patients that achieve clinical remission, relapse occurs once treat-
ment is withdrawn. This suggests that other non-leukocyte targets
need to be addressed if persistent inﬂation is to be resolved. In
this review we have explored the role of stromal cells in disease
pathogenesis and suggest that stromal cells provide an attrac-
tive, site-speciﬁc target for therapy. Combined therapies, aimed
at silencing the stroma, provide an alternative approach to curing
persistent inﬂammatory disease.
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